Compare WAFD & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAFD | COAG |
|---|---|---|
| Founded | 1917 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 1996 | 2026 |
| Metric | WAFD | COAG |
|---|---|---|
| Price | $28.44 | $33.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $34.50 | ★ $62.67 |
| AVG Volume (30 Days) | ★ 1.1M | 360.3K |
| Earning Date | 10-15-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | ★ 5.20 | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $29,650,000.00 | N/A |
| Revenue This Year | $127.22 | N/A |
| Revenue Next Year | $21.56 | N/A |
| P/E Ratio | $11.62 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $28.43 | $27.38 |
| 52 Week High | $39.49 | $55.42 |
| Indicator | WAFD | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 26.93 | 41.76 |
| Support Level | N/A | $28.46 |
| Resistance Level | $33.59 | $33.93 |
| Average True Range (ATR) | 0.61 | 2.28 |
| MACD | 0.07 | 0.50 |
| Stochastic Oscillator | 1.61 | 60.92 |
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.